Summary
Danaher Corporation (DHR) reported strong performance in its 2020 fiscal year, characterized by significant revenue growth driven primarily by the substantial acquisition of Cytiva and robust core sales growth across its segments. The Life Sciences segment showed particular strength, bolstered by Cytiva's performance and demand related to COVID-19 testing and vaccine development. The company navigated the challenges of the COVID-19 pandemic effectively, demonstrating resilience through its diversified business model and the application of the Danaher Business System (DBS). While the pandemic did impact certain areas of the business, overall, Danaher managed operational and financial impacts, leveraging cost-saving measures and adapting to changing market dynamics. The company's strong operating profit margins and cash flow generation underscore its operational efficiency and financial health, positioning it well for continued growth and strategic investments in science and technology.
Financial Highlights
52 data points| Revenue | $22.28B |
| Cost of Revenue | $9.81B |
| Gross Profit | $12.47B |
| R&D Expenses | $1.35B |
| SG&A Expenses | $6.90B |
| Operating Income | $4.23B |
| Interest Expense | $275.00M |
| Net Income | $3.65B |
| EPS (Basic) | $4.97 |
| EPS (Diluted) | $4.89 |
| Shares Outstanding (Basic) | 706.20M |
| Shares Outstanding (Diluted) | 718.70M |
Key Highlights
- 1Danaher reported a 24.5% increase in total sales for 2020, largely driven by the strategic acquisition of Cytiva in March 2020 for approximately $20.7 billion.
- 2Core sales (excluding acquisitions/divestitures and currency impact) grew by 6.5%, with core sales including Cytiva showing a 9.5% increase, demonstrating underlying business strength.
- 3The Life Sciences segment saw significant growth with a 52.0% increase in total sales, primarily due to the Cytiva acquisition and strong demand for bioprocessing instruments and consumables related to COVID-19 vaccine development.
- 4The Diagnostics segment also performed well, with a 13.0% increase in total sales, driven by molecular diagnostics and acute care instruments and consumables, partly due to COVID-19 related demand.
- 5Operating profit margin improved to 19.0% in 2020 from 18.3% in 2019, reflecting operational efficiencies and cost management, despite some acquisition-related charges.
- 6The company generated strong operating cash flow of $6.2 billion in 2020, a 70% increase from 2019, supported by higher earnings and working capital management.
- 7Danaher maintains a strong liquidity position with $6.0 billion in cash and cash equivalents as of December 31, 2020, and substantial availability under its credit facilities.